AngioDynamics (NASDAQ:ANGO) Releases FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO - Get Free Report) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided EPS guidance of ($0.34)-($0.31) for the period, compared to the consensus EPS estimate of ($0.37). The company issued revenue guidance of $285-288 million, compared to the consensus revenue estimate of $284.89 million. AngioDynamics also updated its FY 2025 guidance to -0.340--0.310 EPS.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a "buy" rating and issued a $16.00 target price (up previously from $15.00) on shares of AngioDynamics in a research note on Monday.

AngioDynamics Price Performance

ANGO stock traded down $0.02 during midday trading on Monday, hitting $9.09. The company's stock had a trading volume of 236,377 shares, compared to its average volume of 571,310. The company's fifty day moving average price is $10.16 and its 200 day moving average price is $8.89. AngioDynamics has a twelve month low of $5.47 and a twelve month high of $13.50. The stock has a market capitalization of $367.92 million, a P/E ratio of -1.63 and a beta of 0.52.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Wednesday, April 2nd. The medical instruments supplier reported $0.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.16. AngioDynamics had a negative return on equity of 7.26% and a negative net margin of 79.38%. The business had revenue of $72.00 million for the quarter, compared to the consensus estimate of $70.30 million. The company's quarterly revenue was down 4.3% on a year-over-year basis. Equities analysts expect that AngioDynamics will post -0.37 EPS for the current fiscal year.

Insider Activity

In other AngioDynamics news, SVP Warren Nighan, Jr. sold 4,060 shares of the company's stock in a transaction on Thursday, January 16th. The shares were sold at an average price of $12.31, for a total transaction of $49,978.60. Following the sale, the senior vice president now directly owns 41,817 shares of the company's stock, valued at approximately $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 5.40% of the stock is currently owned by insiders.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.